Literature DB >> 8639180

Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4.

J A van Roon1, J L van Roy, F H Gmelig-Meyling, F P Lafeber, J W Bijlsma.   

Abstract

OBJECTIVE: Inflammation-induced articular cartilage degradation is a major problem in rheumatoid arthritis (RA). Type 1 T cell activity (characterized by interferon-gamma/interleukin-2 [IL-2] production), and consequently, the production of the proinflammatory cytokines IL-1 and tumor necrosis factor alpha (TNF alpha), have been reported to play a major role in cartilage damage. IL-10 and IL-4, both produced by type 2 T cells, are cytokines with the capacity to down-regulate proinflammatory responses. The present study was undertaken to investigate the way in which these cytokines affect activated mononuclear cells (MNC) of RA patients in relation to human articular cartilage degradation in vitro.
METHODS: MNC from synovial fluid and peripheral blood of RA patients were stimulated with bacterial antigen and treated with IL-10 and/or IL-4. Bacterial antigen is known to activate type 1 T cells and to induce proinflammatory IL-1/TNF alpha-dependent cartilage damage. Cytokine production and effects of conditioned media, as well as effects of IL-10 and IL-4 on proteoglycan (PG) turnover (as a measure for cartilage damage), were determined.
RESULTS: IL-10 and IL-4 inhibited proinflammatory cytokine production of stimulated RA MNC and completely reversed inhibition of cartilage PG synthesis induced by these stimulated RA MNC. IL-10 was more potent than IL-4 in this respect, and the combination of IL-10 and IL-4 had an additive effect. In addition, IL-10 directly stimulated cartilage PG synthesis.
CONCLUSION: IL-10 reverses the cartilage degradation induced by antigen-stimulated MNC, and IL-4 has an additive effect on this process. Furthermore, IL-10 has a direct stimulatory effect on PG synthesis, and IL-4, as a growth factor for type 2 T cells, can reduce the ratio of type 1 to type 2 T cell activity. These results provide evidence in favor of the use of a combination of the two cytokines in the treatment of RA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639180     DOI: 10.1002/art.1780390516

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  45 in total

1.  Characterization of phenotype and cytokine profiles of T cell lines derived from vitreous humour in ocular inflammation in man.

Authors:  M Muhaya; V L Calder; H M Towler; G Jolly; M McLauchlan; S Lightman
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

2.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 3.  New therapies in development for autoimmune diseases: their rationale for combination treatment.

Authors:  V Strand
Journal:  Springer Semin Immunopathol       Date:  2001

Review 4.  Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.

Authors:  M R Kok; B J Baum; P P Tak; S R Pillemer
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

5.  Modulation of immune and inflammatory responses on experimental arthritis following intraarticular gene transfer of tumor necrosis factor receptor-immunoglobulin Fc.

Authors:  Xiaobing Zhou; Kai Gao; Lianzhong Shen; Aizhi Zhao; Xiaobing Wu; Chao Wang; Junzhi Wang; Bo Li
Journal:  Rheumatol Int       Date:  2011-07-21       Impact factor: 2.631

6.  Decrease in peripheral type 1 over type 2 T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease.

Authors:  J A van Roon; C M Verhoef; J L van Roy; F H Gmelig-Meyling; O Huber-Bruning; F P Lafeber; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

7.  MicroRNA-9 promotion of interleukin-6 expression by inhibiting monocyte chemoattractant protein-induced protein 1 expression in interleukin-1β-stimulated human chondrocytes.

Authors:  Mohammad S Makki; Abdul Haseeb; Tariq M Haqqi
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

8.  Discovery of New Benzothiazine Derivative as Modulator of Pro- and Anti-inflammatory Cytokines in Rheumatoid Arthritis.

Authors:  Arham Shabbir; Muhammad Shahzad; Akbar Ali; Muhammad Zia-Ur-Rehman
Journal:  Inflammation       Date:  2016-12       Impact factor: 4.092

9.  Dual biological functions of an interleukin-1 receptor antagonist-interleukin-10 fusion protein and its suppressive effects on joint inflammation.

Authors:  Deh-Ming Chang; Song-Kun Shyue; Shao-Hsiang Liu; Yen-Teen Chen; Chiou-Yueh Yeh; Jenn-Huang Lai; Herng-Sheng Lee; Ann Chen
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

10.  IL-10 is critically involved in mycobacterial HSP70 induced suppression of proteoglycan-induced arthritis.

Authors:  Lotte Wieten; Suzanne E Berlo; Corlinda B Ten Brink; Peter J van Kooten; Mahavir Singh; Ruurd van der Zee; Tibor T Glant; Femke Broere; Willem van Eden
Journal:  PLoS One       Date:  2009-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.